Objectives To evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still’s ...

Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...

Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid ...

Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...

Over the last decade, the outlook for patients with rheumatoid arthritis (RA) has improved, but there is growing interest in ...

Objectives DARWIN 3 (ClinicalTrials.gov: NCT02065700) assessed the safety and efficacy of filgotinib in a long-term extension (LTE) of two phase II randomised controlled rheumatoid arthritis (RA) ...

Objectives To identify glucocorticoid (GC) treatment patterns in patients with polymyalgia rheumatica (PMR) and explore patient profiles that may benefit from GC-sparing interventions. Methods This ...

Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...

Background Psoriatic arthritis (PsA) is a multifaceted condition with a broad spectrum of manifestations and a range of associated comorbidities. A notable segment of patients with PsA remains ...

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by the presence of autoantibodies. Their value for diagnostic/prognostic purposes has been well established. In contrast, their ...

Objective Postacute COVID-19 syndrome (PACS) is an emerging entity characterised by a large array of manifestations, including musculoskeletal complaints, fatigue and cognitive or sleep disturbances.

Objectives Compare the risk of extended major adverse cardiovascular (CV) event (MACE) composite outcomes and component events in patients with rheumatoid arthritis (RA) treated with tofacitinib ...